Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody
We have evaluated the role of In‐111 anti‐CEA (carcinoembryonic antigen) monoclonal antibody ZCE 025 in 8 patients. Three patients had a confirmed diagnosis of gastric carcinoma. Three had a confirmed diagnosis of pancreatic carcinoma. Two patients had elevated serum levels of CEA with no known prim...
Gespeichert in:
| Veröffentlicht in: | World journal of surgery 1991-01, Vol.15 (1), p.122-127 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 127 |
|---|---|
| container_issue | 1 |
| container_start_page | 122 |
| container_title | World journal of surgery |
| container_volume | 15 |
| creator | Abdel‐Nabi, Hani H. Schwartz, Alan N. Wechter, Debra G. Higano, Celestia S. Ortman‐Nabi, Judith A. Unger, Michael W. |
| description | We have evaluated the role of In‐111 anti‐CEA (carcinoembryonic antigen) monoclonal antibody ZCE 025 in 8 patients. Three patients had a confirmed diagnosis of gastric carcinoma. Three had a confirmed diagnosis of pancreatic carcinoma. Two patients had elevated serum levels of CEA with no known primary. Each patient received 5.5 mCi In‐111 ZCE 025 infused at doses of 10–80 mg. Planar and single photon emission computed tomography (SPECT) imaging at 3 and 7 days after infusion detected 9 of 12 known tumor sites and all 5 of the previously identified sites of metastasis. In‐111 ZCE 025 MoAb imaging also found 6 previously unsuspected tumor sites and changed the preoperative evaluation in 50% of the patients studied. It changed the clinical management in 2 patients and established the site of primary involvement in 2 others. There were no clinical or biochemical reactions. In‐111 ZCE 025 monoclonal antibody scintigraphy is a useful adjunct in the evaluation of patients with either gastric or pancreatic carcinoma. It may have a beneficial impact on the surgical decision making in these patients.
Résumé
Nous avons étudié le rôle de l'anticorps monoclonal anti ACE ZCE 025 marqué à l'I‐111 chez 8 patients. Trois d'entre eux avaient un diagnostic certain de cancer gastrique. Trois autres avaient un diagnostic certain de cancer du pancréas. Deux autres patients avaient un taux élevé d'antigène carcino‐embryonnaire sans qu'on connaisse l'origine du cancer primitif. Chaque patient avait été perfusé avec 10–80 mg de ZCE 025 à l'In‐111 (5.5 mCi). Trois à 7 jours après, l'imagerie planaire et SPECT a décelé 9 des 12 localisations tumorales primitives et les 5 localisations métastatiques déjà connues. Ces examens ont également mis en évidence 6 autres localisations jusqu'alors insoupÇonnées. L'imagerie par anticorps monoclonal ZCE 025 à l'In‐111 a redressé le bilan préopératoire chez 2 patients et a permis de trouver le cancer primitif chez 2 autres. La scintigraphie avec l'aide des anticorps monoclonaux ZCE 025 à l'In‐111 est utile dans l'évaluation des patients ayant un cancer gastrique ou pancréatique. Elle peut influencer la décision chirurgicale chez ces patients.
Resumen
Hemos realizado la valoración del papel del anticuerpo monoclonal In‐111 anti‐CEA ZCE 025 en 8 pacientes. Tres tenían diagnóstico confirmado de carcinoma gástrico y 3 de carcinoma pancreático. Dos pacientes exhibieron nivelés séricos elevados de antigeno carcinoembriónico en ausencia de una neoplas |
| doi_str_mv | 10.1007/BF01658982 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_6059965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80443177</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3552-c8316f292f6c79809723c8f14ba3cfa7f21dc5ac87f83423588991535ecbac593</originalsourceid><addsrcrecordid>eNp9kL1qHDEUhYWJcTZOGveBIUWKwNr6GWmkMl7s2MbgwgmBNEJ7R9pVmJE2khaznR8hj5Bn8aP4SSIzBqdKdf--e-AchI4IPiYYdyen55gILpWke2hGWkbnlFH2Cs0wE23tCXuN3uT8E2PSCSwO0AFRquVKzNDqFnwofpXMZu2h6W2xUHwMTXTNyuSS6tKEvtmYAMmaUkcwqf7E0eTmzpd1cxke738TQpofi7MGU_7wZ4whwhCDGepv8cvY796ifWeGbN8910P07fzs6-Jifn3z5XLx-XoOjHM6B8mIcFRRJ6BTEquOMpCOtEvDwJnOUdIDNyA7J1lLGZdSKcIZt7A0wBU7RB8m3ZiL1xl89bOGGEK1pQXmSgleoY8TtEnx19bmokefwQ6DCTZus5a4bRnpugp-mkBIMedknd4kP5q00wTrp-j1S_QVfv-sul2Otn9Bp6zrnU_3Oz_Y3X-U9Per2390_wJiO43J</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80443177</pqid></control><display><type>article</type><title>Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Abdel‐Nabi, Hani H. ; Schwartz, Alan N. ; Wechter, Debra G. ; Higano, Celestia S. ; Ortman‐Nabi, Judith A. ; Unger, Michael W.</creator><creatorcontrib>Abdel‐Nabi, Hani H. ; Schwartz, Alan N. ; Wechter, Debra G. ; Higano, Celestia S. ; Ortman‐Nabi, Judith A. ; Unger, Michael W.</creatorcontrib><description>We have evaluated the role of In‐111 anti‐CEA (carcinoembryonic antigen) monoclonal antibody ZCE 025 in 8 patients. Three patients had a confirmed diagnosis of gastric carcinoma. Three had a confirmed diagnosis of pancreatic carcinoma. Two patients had elevated serum levels of CEA with no known primary. Each patient received 5.5 mCi In‐111 ZCE 025 infused at doses of 10–80 mg. Planar and single photon emission computed tomography (SPECT) imaging at 3 and 7 days after infusion detected 9 of 12 known tumor sites and all 5 of the previously identified sites of metastasis. In‐111 ZCE 025 MoAb imaging also found 6 previously unsuspected tumor sites and changed the preoperative evaluation in 50% of the patients studied. It changed the clinical management in 2 patients and established the site of primary involvement in 2 others. There were no clinical or biochemical reactions. In‐111 ZCE 025 monoclonal antibody scintigraphy is a useful adjunct in the evaluation of patients with either gastric or pancreatic carcinoma. It may have a beneficial impact on the surgical decision making in these patients.
Résumé
Nous avons étudié le rôle de l'anticorps monoclonal anti ACE ZCE 025 marqué à l'I‐111 chez 8 patients. Trois d'entre eux avaient un diagnostic certain de cancer gastrique. Trois autres avaient un diagnostic certain de cancer du pancréas. Deux autres patients avaient un taux élevé d'antigène carcino‐embryonnaire sans qu'on connaisse l'origine du cancer primitif. Chaque patient avait été perfusé avec 10–80 mg de ZCE 025 à l'In‐111 (5.5 mCi). Trois à 7 jours après, l'imagerie planaire et SPECT a décelé 9 des 12 localisations tumorales primitives et les 5 localisations métastatiques déjà connues. Ces examens ont également mis en évidence 6 autres localisations jusqu'alors insoupÇonnées. L'imagerie par anticorps monoclonal ZCE 025 à l'In‐111 a redressé le bilan préopératoire chez 2 patients et a permis de trouver le cancer primitif chez 2 autres. La scintigraphie avec l'aide des anticorps monoclonaux ZCE 025 à l'In‐111 est utile dans l'évaluation des patients ayant un cancer gastrique ou pancréatique. Elle peut influencer la décision chirurgicale chez ces patients.
Resumen
Hemos realizado la valoración del papel del anticuerpo monoclonal In‐111 anti‐CEA ZCE 025 en 8 pacientes. Tres tenían diagnóstico confirmado de carcinoma gástrico y 3 de carcinoma pancreático. Dos pacientes exhibieron nivelés séricos elevados de antigeno carcinoembriónico en ausencia de una neoplasia primaria conocida. Cada paciente recibió 5.5 mCi In‐111 ZCE 025 en infusión a dosis de 10–80 mg. Imágenes planares y SPECT tomadas a los 3 y 7 días después de la infusión detectaron 9 de 12 ubicaciones tumorales conocidas y todos los 5 lugares de metástasis previamente identificados. También encontró 6 ubicaciones metastásicas previamente no sospechadas. Las imágenes con In‐111 ZCE 025 MoAb cambiaron la evaluación preoperatoria en 50% de los pacientes estudiados y permitió definir el lugar de la afección primaria en otros dos. No se observaron reacciones clinicas ni bioquimicas adversas. La escintigrafía con el anticuerpo monoclonal es un adyuvante Útil en la evaluación de pacientes con carcinoma gástrico o carcinoma pancreático. Puede tener un impacto beneficioso sobre el proceso de decision quirÚrgica.</description><identifier>ISSN: 0364-2313</identifier><identifier>EISSN: 1432-2323</identifier><identifier>DOI: 10.1007/BF01658982</identifier><identifier>PMID: 1994596</identifier><language>eng</language><publisher>New York: Springer‐Verlag</publisher><subject>550601 - Medicine- Unsealed Radionuclides in Diagnostics ; Adult ; Aged ; ANTIBODIES ; Antibodies, Monoclonal ; BETA DECAY RADIOISOTOPES ; BODY ; Carcinoembryonic Antigen - immunology ; Carcinoma ; CARCINOMAS ; CEA ; COMPUTERIZED TOMOGRAPHY ; COUNTING TECHNIQUES ; DAYS LIVING RADIOISOTOPES ; DECISION MAKING ; DIAGNOSIS ; DIAGNOSTIC TECHNIQUES ; DIGESTIVE SYSTEM ; DISEASES ; ELECTRON CAPTURE RADIOISOTOPES ; EMISSION COMPUTED TOMOGRAPHY ; ENDOCRINE GLANDS ; Female ; FRENCH ORGANIZATIONS ; Gastric Carcinoma ; GASTROINTESTINAL TRACT ; GLANDS ; Humans ; IMAGE PROCESSING ; INDIUM 111 ; INDIUM ISOTOPES ; Indium Radioisotopes ; INTERMEDIATE MASS NUCLEI ; ISOMERIC TRANSITION ISOTOPES ; ISOTOPE APPLICATIONS ; ISOTOPES ; Male ; Middle Aged ; MINUTES LIVING RADIOISOTOPES ; MONOCLONAL ANTIBODIES ; NATIONAL ORGANIZATIONS ; NEOPLASMS ; NUCLEI ; ODD-EVEN NUCLEI ; ORGANS ; PANCREAS ; Pancreatic Carcinoma ; Pancreatic Neoplasms - diagnostic imaging ; PATIENTS ; PROCESSING ; RADIOIMMUNODETECTION ; RADIOIMMUNOSCINTIGRAPHY ; RADIOISOTOPE SCANNING ; RADIOISOTOPES ; RADIOLOGY AND NUCLEAR MEDICINE ; Radionuclide Imaging ; SCINTISCANNING ; Single Photon Emission Compute Tomography ; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY ; SPECIFICITY ; Stomach Neoplasms - diagnostic imaging ; TOMOGRAPHY ; Tomography, X-Ray Computed ; TRACER TECHNIQUES ; Tumor Site</subject><ispartof>World journal of surgery, 1991-01, Vol.15 (1), p.122-127</ispartof><rights>1991 International Society of Surgery</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3552-c8316f292f6c79809723c8f14ba3cfa7f21dc5ac87f83423588991535ecbac593</citedby><cites>FETCH-LOGICAL-c3552-c8316f292f6c79809723c8f14ba3cfa7f21dc5ac87f83423588991535ecbac593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1994596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/6059965$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdel‐Nabi, Hani H.</creatorcontrib><creatorcontrib>Schwartz, Alan N.</creatorcontrib><creatorcontrib>Wechter, Debra G.</creatorcontrib><creatorcontrib>Higano, Celestia S.</creatorcontrib><creatorcontrib>Ortman‐Nabi, Judith A.</creatorcontrib><creatorcontrib>Unger, Michael W.</creatorcontrib><title>Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody</title><title>World journal of surgery</title><addtitle>World J Surg</addtitle><description>We have evaluated the role of In‐111 anti‐CEA (carcinoembryonic antigen) monoclonal antibody ZCE 025 in 8 patients. Three patients had a confirmed diagnosis of gastric carcinoma. Three had a confirmed diagnosis of pancreatic carcinoma. Two patients had elevated serum levels of CEA with no known primary. Each patient received 5.5 mCi In‐111 ZCE 025 infused at doses of 10–80 mg. Planar and single photon emission computed tomography (SPECT) imaging at 3 and 7 days after infusion detected 9 of 12 known tumor sites and all 5 of the previously identified sites of metastasis. In‐111 ZCE 025 MoAb imaging also found 6 previously unsuspected tumor sites and changed the preoperative evaluation in 50% of the patients studied. It changed the clinical management in 2 patients and established the site of primary involvement in 2 others. There were no clinical or biochemical reactions. In‐111 ZCE 025 monoclonal antibody scintigraphy is a useful adjunct in the evaluation of patients with either gastric or pancreatic carcinoma. It may have a beneficial impact on the surgical decision making in these patients.
Résumé
Nous avons étudié le rôle de l'anticorps monoclonal anti ACE ZCE 025 marqué à l'I‐111 chez 8 patients. Trois d'entre eux avaient un diagnostic certain de cancer gastrique. Trois autres avaient un diagnostic certain de cancer du pancréas. Deux autres patients avaient un taux élevé d'antigène carcino‐embryonnaire sans qu'on connaisse l'origine du cancer primitif. Chaque patient avait été perfusé avec 10–80 mg de ZCE 025 à l'In‐111 (5.5 mCi). Trois à 7 jours après, l'imagerie planaire et SPECT a décelé 9 des 12 localisations tumorales primitives et les 5 localisations métastatiques déjà connues. Ces examens ont également mis en évidence 6 autres localisations jusqu'alors insoupÇonnées. L'imagerie par anticorps monoclonal ZCE 025 à l'In‐111 a redressé le bilan préopératoire chez 2 patients et a permis de trouver le cancer primitif chez 2 autres. La scintigraphie avec l'aide des anticorps monoclonaux ZCE 025 à l'In‐111 est utile dans l'évaluation des patients ayant un cancer gastrique ou pancréatique. Elle peut influencer la décision chirurgicale chez ces patients.
Resumen
Hemos realizado la valoración del papel del anticuerpo monoclonal In‐111 anti‐CEA ZCE 025 en 8 pacientes. Tres tenían diagnóstico confirmado de carcinoma gástrico y 3 de carcinoma pancreático. Dos pacientes exhibieron nivelés séricos elevados de antigeno carcinoembriónico en ausencia de una neoplasia primaria conocida. Cada paciente recibió 5.5 mCi In‐111 ZCE 025 en infusión a dosis de 10–80 mg. Imágenes planares y SPECT tomadas a los 3 y 7 días después de la infusión detectaron 9 de 12 ubicaciones tumorales conocidas y todos los 5 lugares de metástasis previamente identificados. También encontró 6 ubicaciones metastásicas previamente no sospechadas. Las imágenes con In‐111 ZCE 025 MoAb cambiaron la evaluación preoperatoria en 50% de los pacientes estudiados y permitió definir el lugar de la afección primaria en otros dos. No se observaron reacciones clinicas ni bioquimicas adversas. La escintigrafía con el anticuerpo monoclonal es un adyuvante Útil en la evaluación de pacientes con carcinoma gástrico o carcinoma pancreático. Puede tener un impacto beneficioso sobre el proceso de decision quirÚrgica.</description><subject>550601 - Medicine- Unsealed Radionuclides in Diagnostics</subject><subject>Adult</subject><subject>Aged</subject><subject>ANTIBODIES</subject><subject>Antibodies, Monoclonal</subject><subject>BETA DECAY RADIOISOTOPES</subject><subject>BODY</subject><subject>Carcinoembryonic Antigen - immunology</subject><subject>Carcinoma</subject><subject>CARCINOMAS</subject><subject>CEA</subject><subject>COMPUTERIZED TOMOGRAPHY</subject><subject>COUNTING TECHNIQUES</subject><subject>DAYS LIVING RADIOISOTOPES</subject><subject>DECISION MAKING</subject><subject>DIAGNOSIS</subject><subject>DIAGNOSTIC TECHNIQUES</subject><subject>DIGESTIVE SYSTEM</subject><subject>DISEASES</subject><subject>ELECTRON CAPTURE RADIOISOTOPES</subject><subject>EMISSION COMPUTED TOMOGRAPHY</subject><subject>ENDOCRINE GLANDS</subject><subject>Female</subject><subject>FRENCH ORGANIZATIONS</subject><subject>Gastric Carcinoma</subject><subject>GASTROINTESTINAL TRACT</subject><subject>GLANDS</subject><subject>Humans</subject><subject>IMAGE PROCESSING</subject><subject>INDIUM 111</subject><subject>INDIUM ISOTOPES</subject><subject>Indium Radioisotopes</subject><subject>INTERMEDIATE MASS NUCLEI</subject><subject>ISOMERIC TRANSITION ISOTOPES</subject><subject>ISOTOPE APPLICATIONS</subject><subject>ISOTOPES</subject><subject>Male</subject><subject>Middle Aged</subject><subject>MINUTES LIVING RADIOISOTOPES</subject><subject>MONOCLONAL ANTIBODIES</subject><subject>NATIONAL ORGANIZATIONS</subject><subject>NEOPLASMS</subject><subject>NUCLEI</subject><subject>ODD-EVEN NUCLEI</subject><subject>ORGANS</subject><subject>PANCREAS</subject><subject>Pancreatic Carcinoma</subject><subject>Pancreatic Neoplasms - diagnostic imaging</subject><subject>PATIENTS</subject><subject>PROCESSING</subject><subject>RADIOIMMUNODETECTION</subject><subject>RADIOIMMUNOSCINTIGRAPHY</subject><subject>RADIOISOTOPE SCANNING</subject><subject>RADIOISOTOPES</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Radionuclide Imaging</subject><subject>SCINTISCANNING</subject><subject>Single Photon Emission Compute Tomography</subject><subject>SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY</subject><subject>SPECIFICITY</subject><subject>Stomach Neoplasms - diagnostic imaging</subject><subject>TOMOGRAPHY</subject><subject>Tomography, X-Ray Computed</subject><subject>TRACER TECHNIQUES</subject><subject>Tumor Site</subject><issn>0364-2313</issn><issn>1432-2323</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kL1qHDEUhYWJcTZOGveBIUWKwNr6GWmkMl7s2MbgwgmBNEJ7R9pVmJE2khaznR8hj5Bn8aP4SSIzBqdKdf--e-AchI4IPiYYdyen55gILpWke2hGWkbnlFH2Cs0wE23tCXuN3uT8E2PSCSwO0AFRquVKzNDqFnwofpXMZu2h6W2xUHwMTXTNyuSS6tKEvtmYAMmaUkcwqf7E0eTmzpd1cxke738TQpofi7MGU_7wZ4whwhCDGepv8cvY796ifWeGbN8910P07fzs6-Jifn3z5XLx-XoOjHM6B8mIcFRRJ6BTEquOMpCOtEvDwJnOUdIDNyA7J1lLGZdSKcIZt7A0wBU7RB8m3ZiL1xl89bOGGEK1pQXmSgleoY8TtEnx19bmokefwQ6DCTZus5a4bRnpugp-mkBIMedknd4kP5q00wTrp-j1S_QVfv-sul2Otn9Bp6zrnU_3Oz_Y3X-U9Per2390_wJiO43J</recordid><startdate>199101</startdate><enddate>199101</enddate><creator>Abdel‐Nabi, Hani H.</creator><creator>Schwartz, Alan N.</creator><creator>Wechter, Debra G.</creator><creator>Higano, Celestia S.</creator><creator>Ortman‐Nabi, Judith A.</creator><creator>Unger, Michael W.</creator><general>Springer‐Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>199101</creationdate><title>Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody</title><author>Abdel‐Nabi, Hani H. ; Schwartz, Alan N. ; Wechter, Debra G. ; Higano, Celestia S. ; Ortman‐Nabi, Judith A. ; Unger, Michael W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3552-c8316f292f6c79809723c8f14ba3cfa7f21dc5ac87f83423588991535ecbac593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>550601 - Medicine- Unsealed Radionuclides in Diagnostics</topic><topic>Adult</topic><topic>Aged</topic><topic>ANTIBODIES</topic><topic>Antibodies, Monoclonal</topic><topic>BETA DECAY RADIOISOTOPES</topic><topic>BODY</topic><topic>Carcinoembryonic Antigen - immunology</topic><topic>Carcinoma</topic><topic>CARCINOMAS</topic><topic>CEA</topic><topic>COMPUTERIZED TOMOGRAPHY</topic><topic>COUNTING TECHNIQUES</topic><topic>DAYS LIVING RADIOISOTOPES</topic><topic>DECISION MAKING</topic><topic>DIAGNOSIS</topic><topic>DIAGNOSTIC TECHNIQUES</topic><topic>DIGESTIVE SYSTEM</topic><topic>DISEASES</topic><topic>ELECTRON CAPTURE RADIOISOTOPES</topic><topic>EMISSION COMPUTED TOMOGRAPHY</topic><topic>ENDOCRINE GLANDS</topic><topic>Female</topic><topic>FRENCH ORGANIZATIONS</topic><topic>Gastric Carcinoma</topic><topic>GASTROINTESTINAL TRACT</topic><topic>GLANDS</topic><topic>Humans</topic><topic>IMAGE PROCESSING</topic><topic>INDIUM 111</topic><topic>INDIUM ISOTOPES</topic><topic>Indium Radioisotopes</topic><topic>INTERMEDIATE MASS NUCLEI</topic><topic>ISOMERIC TRANSITION ISOTOPES</topic><topic>ISOTOPE APPLICATIONS</topic><topic>ISOTOPES</topic><topic>Male</topic><topic>Middle Aged</topic><topic>MINUTES LIVING RADIOISOTOPES</topic><topic>MONOCLONAL ANTIBODIES</topic><topic>NATIONAL ORGANIZATIONS</topic><topic>NEOPLASMS</topic><topic>NUCLEI</topic><topic>ODD-EVEN NUCLEI</topic><topic>ORGANS</topic><topic>PANCREAS</topic><topic>Pancreatic Carcinoma</topic><topic>Pancreatic Neoplasms - diagnostic imaging</topic><topic>PATIENTS</topic><topic>PROCESSING</topic><topic>RADIOIMMUNODETECTION</topic><topic>RADIOIMMUNOSCINTIGRAPHY</topic><topic>RADIOISOTOPE SCANNING</topic><topic>RADIOISOTOPES</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Radionuclide Imaging</topic><topic>SCINTISCANNING</topic><topic>Single Photon Emission Compute Tomography</topic><topic>SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY</topic><topic>SPECIFICITY</topic><topic>Stomach Neoplasms - diagnostic imaging</topic><topic>TOMOGRAPHY</topic><topic>Tomography, X-Ray Computed</topic><topic>TRACER TECHNIQUES</topic><topic>Tumor Site</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdel‐Nabi, Hani H.</creatorcontrib><creatorcontrib>Schwartz, Alan N.</creatorcontrib><creatorcontrib>Wechter, Debra G.</creatorcontrib><creatorcontrib>Higano, Celestia S.</creatorcontrib><creatorcontrib>Ortman‐Nabi, Judith A.</creatorcontrib><creatorcontrib>Unger, Michael W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>World journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdel‐Nabi, Hani H.</au><au>Schwartz, Alan N.</au><au>Wechter, Debra G.</au><au>Higano, Celestia S.</au><au>Ortman‐Nabi, Judith A.</au><au>Unger, Michael W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody</atitle><jtitle>World journal of surgery</jtitle><addtitle>World J Surg</addtitle><date>1991-01</date><risdate>1991</risdate><volume>15</volume><issue>1</issue><spage>122</spage><epage>127</epage><pages>122-127</pages><issn>0364-2313</issn><eissn>1432-2323</eissn><abstract>We have evaluated the role of In‐111 anti‐CEA (carcinoembryonic antigen) monoclonal antibody ZCE 025 in 8 patients. Three patients had a confirmed diagnosis of gastric carcinoma. Three had a confirmed diagnosis of pancreatic carcinoma. Two patients had elevated serum levels of CEA with no known primary. Each patient received 5.5 mCi In‐111 ZCE 025 infused at doses of 10–80 mg. Planar and single photon emission computed tomography (SPECT) imaging at 3 and 7 days after infusion detected 9 of 12 known tumor sites and all 5 of the previously identified sites of metastasis. In‐111 ZCE 025 MoAb imaging also found 6 previously unsuspected tumor sites and changed the preoperative evaluation in 50% of the patients studied. It changed the clinical management in 2 patients and established the site of primary involvement in 2 others. There were no clinical or biochemical reactions. In‐111 ZCE 025 monoclonal antibody scintigraphy is a useful adjunct in the evaluation of patients with either gastric or pancreatic carcinoma. It may have a beneficial impact on the surgical decision making in these patients.
Résumé
Nous avons étudié le rôle de l'anticorps monoclonal anti ACE ZCE 025 marqué à l'I‐111 chez 8 patients. Trois d'entre eux avaient un diagnostic certain de cancer gastrique. Trois autres avaient un diagnostic certain de cancer du pancréas. Deux autres patients avaient un taux élevé d'antigène carcino‐embryonnaire sans qu'on connaisse l'origine du cancer primitif. Chaque patient avait été perfusé avec 10–80 mg de ZCE 025 à l'In‐111 (5.5 mCi). Trois à 7 jours après, l'imagerie planaire et SPECT a décelé 9 des 12 localisations tumorales primitives et les 5 localisations métastatiques déjà connues. Ces examens ont également mis en évidence 6 autres localisations jusqu'alors insoupÇonnées. L'imagerie par anticorps monoclonal ZCE 025 à l'In‐111 a redressé le bilan préopératoire chez 2 patients et a permis de trouver le cancer primitif chez 2 autres. La scintigraphie avec l'aide des anticorps monoclonaux ZCE 025 à l'In‐111 est utile dans l'évaluation des patients ayant un cancer gastrique ou pancréatique. Elle peut influencer la décision chirurgicale chez ces patients.
Resumen
Hemos realizado la valoración del papel del anticuerpo monoclonal In‐111 anti‐CEA ZCE 025 en 8 pacientes. Tres tenían diagnóstico confirmado de carcinoma gástrico y 3 de carcinoma pancreático. Dos pacientes exhibieron nivelés séricos elevados de antigeno carcinoembriónico en ausencia de una neoplasia primaria conocida. Cada paciente recibió 5.5 mCi In‐111 ZCE 025 en infusión a dosis de 10–80 mg. Imágenes planares y SPECT tomadas a los 3 y 7 días después de la infusión detectaron 9 de 12 ubicaciones tumorales conocidas y todos los 5 lugares de metástasis previamente identificados. También encontró 6 ubicaciones metastásicas previamente no sospechadas. Las imágenes con In‐111 ZCE 025 MoAb cambiaron la evaluación preoperatoria en 50% de los pacientes estudiados y permitió definir el lugar de la afección primaria en otros dos. No se observaron reacciones clinicas ni bioquimicas adversas. La escintigrafía con el anticuerpo monoclonal es un adyuvante Útil en la evaluación de pacientes con carcinoma gástrico o carcinoma pancreático. Puede tener un impacto beneficioso sobre el proceso de decision quirÚrgica.</abstract><cop>New York</cop><pub>Springer‐Verlag</pub><pmid>1994596</pmid><doi>10.1007/BF01658982</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0364-2313 |
| ispartof | World journal of surgery, 1991-01, Vol.15 (1), p.122-127 |
| issn | 0364-2313 1432-2323 |
| language | eng |
| recordid | cdi_osti_scitechconnect_6059965 |
| source | MEDLINE; SpringerNature Journals |
| subjects | 550601 - Medicine- Unsealed Radionuclides in Diagnostics Adult Aged ANTIBODIES Antibodies, Monoclonal BETA DECAY RADIOISOTOPES BODY Carcinoembryonic Antigen - immunology Carcinoma CARCINOMAS CEA COMPUTERIZED TOMOGRAPHY COUNTING TECHNIQUES DAYS LIVING RADIOISOTOPES DECISION MAKING DIAGNOSIS DIAGNOSTIC TECHNIQUES DIGESTIVE SYSTEM DISEASES ELECTRON CAPTURE RADIOISOTOPES EMISSION COMPUTED TOMOGRAPHY ENDOCRINE GLANDS Female FRENCH ORGANIZATIONS Gastric Carcinoma GASTROINTESTINAL TRACT GLANDS Humans IMAGE PROCESSING INDIUM 111 INDIUM ISOTOPES Indium Radioisotopes INTERMEDIATE MASS NUCLEI ISOMERIC TRANSITION ISOTOPES ISOTOPE APPLICATIONS ISOTOPES Male Middle Aged MINUTES LIVING RADIOISOTOPES MONOCLONAL ANTIBODIES NATIONAL ORGANIZATIONS NEOPLASMS NUCLEI ODD-EVEN NUCLEI ORGANS PANCREAS Pancreatic Carcinoma Pancreatic Neoplasms - diagnostic imaging PATIENTS PROCESSING RADIOIMMUNODETECTION RADIOIMMUNOSCINTIGRAPHY RADIOISOTOPE SCANNING RADIOISOTOPES RADIOLOGY AND NUCLEAR MEDICINE Radionuclide Imaging SCINTISCANNING Single Photon Emission Compute Tomography SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY SPECIFICITY Stomach Neoplasms - diagnostic imaging TOMOGRAPHY Tomography, X-Ray Computed TRACER TECHNIQUES Tumor Site |
| title | Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T23%3A13%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Scintigraphic%20detection%20of%20gastric%20and%20pancreatic%20carcinomas%20with%20In%E2%80%90111%20ZCE%20025%C2%A0monoclonal%20antibody&rft.jtitle=World%20journal%20of%20surgery&rft.au=Abdel%E2%80%90Nabi,%20Hani%20H.&rft.date=1991-01&rft.volume=15&rft.issue=1&rft.spage=122&rft.epage=127&rft.pages=122-127&rft.issn=0364-2313&rft.eissn=1432-2323&rft_id=info:doi/10.1007/BF01658982&rft_dat=%3Cproquest_osti_%3E80443177%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80443177&rft_id=info:pmid/1994596&rfr_iscdi=true |